Nexentis Technologies Inc. (NXTS)
NASDAQ: NXTS · Real-Time Price · USD
0.5623
+0.0381 (7.27%)
At close: Oct 26, 2026, 4:00 PM EDT
0.540605
-0.0217 (-3.86%)
Pre-market: Oct 27, 2026, 7:35 AM EDT
Nexentis Technologies Employees
As of December 31, 2025, Nexentis Technologies had 9 total employees, including 7 full-time and 2 part-time employees. The number of employees increased by 4 or 80.00% compared to the previous year. That makes Nexentis Technologies the 40,508th largest employer in the world and 6,112th in the United States.
Employees
9
Change (1Y)
4
Growth (1Y)
80.00%
Revenue / Employee
n/a
Profits / Employee
-$1,780,778
Market Cap
817.21K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 9 | 4 | 80.00% | 7 | 2 |
| Dec 31, 2024 | 5 | 2 | 66.67% | 3 | 2 |
| Dec 31, 2023 | 3 | -5 | -62.50% | 2 | 1 |
| Dec 31, 2022 | 8 | -2 | -20.00% | 6 | 2 |
| Dec 31, 2021 | 10 | 4 | 66.67% | 9 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Corteva | 21,500 |
| The Mosaic Company | 13,249 |
| ICL Group | 12,000 |
| FMC Corporation | 5,500 |
| The Scotts Miracle-Gro Company | 5,200 |
| CF Industries Holdings | 2,900 |
| Bioceres Crop Solutions | 751 |
| American Vanguard | 739 |
NXTS News
- 23 hours ago - Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage - GlobeNewsWire
- 20 days ago - Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud - GlobeNewsWire
- 4 weeks ago - Nexentis Technologies appoints Major to Scientific Advisory Board - TheFly
- 4 weeks ago - Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board - GlobeNewsWire
- 4 weeks ago - Nexentis subsidiary evaluates ways for obtaining proteins in in-vitro research - TheFly
- 4 weeks ago - Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery - GlobeNewsWire
- 3 months ago - Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign - GlobeNewsWire
- 3 months ago - Nexentis Technologies registers to sell 2.57M shares of common stock for holders - TheFly